Frontier Medicines Presents Preclinical Data on 3 Programs
Frontier Medicines reported preclinical signals across three oncology programs: FMC-376 suppressed tumor growth in KRAS G12C-mutant patient-derived xenograft models,...
Femasys Begins New FemBloc® Birth Control Study in Europe
Femasys has initiated a post‑market surveillance clinical study for its CE‑marked FemBloc permanent birth control device in Europe, structured...
Alector Reveals Topline Data for Phase 3 FTD Drug Trial
In the 96-week Phase 3 INFRONT-3 study in FTD due to GRN mutations, latozinemab failed to slow clinical progression...
Fortress Doses First Patients in Pivotal Gout Drug Trial
Crystalys Therapeutics has dosed the first patients in two global, randomized, double-blind Phase 3 trials of dotinurad, a once-daily...
New Clinical Sites Added for BriaCell’s Phase 3 Cancer Trial
Seventy-nine U.S. sites across 23 states are now open in BriaCell’s pivotal Phase 3 program in metastatic breast cancer,...
Clearmind’s New AUD Trial Completes First Cohort Enrollment
Clearmind Medicine has completed enrollment of the six-patient first cohort in its Phase I/IIa study of CMND-100, an oral...
Eleva Advances C3G Drug CPV-104 into Phase 1b Trial
Eleva completed the single-ascending dose portion of its first-in-human study of CPV-104, a recombinant human Factor H, in 21...
Ogsiveo Trial Shows Long-Term Efficacy for Desmoid Tumors
Objective response on nirogacestat improved from 34.3% at year one to 45.7% with continuous treatment for up to four...
PIVOT-PO Data: A New Hope for Oral cUTI Antibiotic Needs
Non-inferiority was achieved in the pivotal Phase 3 PIVOT-PO trial of oral tebipenem HBr for complicated urinary tract infections,...
Neuphoria Updates Phase 3 Trial for Social Anxiety Drug
Neuphoria’s Phase 3 AFFIRM-1 study of BNC210 for the acute treatment of social anxiety disorder failed to demonstrate efficacy....